Global Chronic Plaque Psoriasis Data 2025, Forecast To 2034
12 Mar, 2025
What Has Been Chronic Plaque Psoriasis Market in Recent Years?
The chronic plaque psoriasis market has seen considerable growth due to a variety of factors.
• The market size for chronic plaque psoriasis has experienced significant growth in the last few years. This market is projected to expand from $20.79 billion in 2024 to $22.32 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.3%.
The prior growth period's expansion can be accredited to several factors including the swell in psoriasis cases, a surge in concurrent health conditions, advantageous reimbursement policies, an increase in alcohol and smoking consumption, and the evolution of telemedicine.
What Is the Forecasted Market Size and Growth Rate for The Chronic Plaque Psoriasis Market?
The chronic plaque psoriasis market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for chronic plaque psoriasis is anticipated to witness robust expansion in the coming years. It is projected to reach $29.33 billion by 2029 with a compound annual growth rate (CAGR) of 7.1%.
The growth during the forecast period can be ascribed to the global fluctuations in the prevalence of cpp, escalation in autoimmune diseases, expansion in healthcare budgets, ageing demographic, and growing demand for effective treatments. Major trends during the forecast period encompass developments in biologic therapies, oral small molecule inhibitors, the integration of digital health, personalized medicine and the introduction of biosimilars.
What Are The Key Drivers Fueling Growth In The Chronic Plaque Psoriasis Market?
The rise in immune system disorders is poised to stimulate the expansion of the chronic plaque psoriasis market. The term immune system dysfunction describes situations where the immune system is unable to function properly, leading to an increased vulnerability to infections, autoimmune diseases, and cancer. The surge in immune system disorders is linked to factors like genetic factors, environmental triggers, poor nutrition, chronic stress, and the growing incidence of autoimmune diseases and infections such as HIV. Treatment for chronic plaque psoriasis is necessary to manage immune system disorders since the immune system causes an excessive production of skin cells leading to inflammation and plaque formation. For instance, in December 2022, the US-based nonprofit, the National Psoriasis Foundation, announced that psoriasis affects more than 8 million Americans. On a global scale, the condition affects 125 million people, which makes up 2 to 3% of the entire population. Consequently, the escalating number of immune system disorders is fuelling the growth of the chronic plaque psoriasis market.
What Key Areas Define The Segmentation Of The Global Chronic Plaque Psoriasis Market?
The chronic plaque psoriasis market covered in this report is segmented –
1) By Drug Class: Biologics, Small Molecule Drugs
2) By Route Of Administration: Injectable, Oral, Topical
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
Subsegments:
1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-2), T-Cell Inhibitors, Others
2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids, Others
How Are Emerging Trends Reshaping The Dynamics Of The Chronic Plaque Psoriasis Market?
Primary businesses within the chronic plaque psoriasis industry are concentrating their efforts on creating unique treatments such as IL-17A and IL-17F inhibitors in order to advance chronic plaque psoriasis treatment methodologies. These inhibitors serve as targeted biotherapeutic treatments that obstruct interleukin-17A as well as interleukin-17F, which are cytokines that spur inflammation in the immune response, particularly in autoimmune disorders such as chronic plaque psoriasis. For instance, UCB S.A., a biopharmaceutical organisation rooted in Belgium, reported in October 2023 that BIMZELX (bimekizumab-bkzx), the first medication specifically tailored for psoriasis to counteract interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key instigators of inflammatory cases, had been approved by the U.S Food and Drug Administration (FDA) for use by adults suffering from moderate to severe plaque psoriasis, who are suitable candidates for systemic therapy or phototherapy. Its approval was based on data collected from three multicentre Phase 3 trials - BE READY, BE VIVID and BE SURE, that jointly evaluated its safety and effectiveness in 1,480 moderate to severe plaque psoriasis patients.
Who Are the Key Players in the Chronic Plaque Psoriasis Market?
Major companies operating in the chronic plaque psoriasis market are include:
• Pfizer Inc.
• Johnson & Johnson
• Merck & Co. Inc.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim
• Biogen Inc.
• UCB S.A.
• Dr. Reddy’s Laboratories
• Innovent Biologics Inc.
• Dong-A ST Co. Ltd.
• Alumis GmbH Co KG
• Zai Lab Limited
• GC Cell Corporation
• Affibody AB
• Nimbus Therapeutics
• Bio-Thera Solutions
• Can-Fite Biopharma
• Celgene Corporation
• Kadmon Pharmaceuticals
• Aldeyra Therapeutics Inc.
• Arcutis Biotherapeutics
What Is The Most Dominant Region In The Chronic Plaque Psoriasis Market?
North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.